ArticleJournal of clinical laboratory analysis2020
Long non-coding RNA KDM5B anti-sense RNA 1 enhances tumor progression in non-small cell lung cancer.
Article in Journal of clinical laboratory analysis, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 9 citations in OpenAlex.
- Prostate cancer-associated transcript 6 (PCAT6) promotes epithelial-mesenchymal transition and stemness and worsens prognosis in patients with colorectal cancer.Acta biochimica et biophysica Sinica · 2024Article
- Review
- Long non‑coding RNA SNHG3 promotes the development of non‑small cell lung cancer via the miR‑1343‑3p/NFIX pathway.International journal of molecular medicine · 2021Article
- Circular RNA circ-LDLRAD3 serves as an oncogene to promote non-small cell lung cancer progression by upregulating SLC1A5 through sponging miR-137.RNA biology · 2020Article
- CircRNA_103762 promotes multidrug resistance in NSCLC by targeting DNA damage inducible transcript 3 (CHOP).Journal of clinical laboratory analysis · 2020Article
- Long noncoding RNAs in osteosarcoma via various signaling pathways.Journal of clinical laboratory analysis · 2020Review
- Circular RNA SMARCA5 may serve as a tumor suppressor in non-small cell lung cancer.Journal of clinical laboratory analysis · 2020Article
- LncRNA-SARCC sensitizes osteosarcoma to cisplatin through the miR-143-mediated glycolysis inhibition by targeting Hexokinase 2.Cancer biomarkers : section A of Disease markers · 2020Article
- Long non-coding RNA KDM5B anti-sense RNA 1 enhances tumor progression in non-small cell lung cancer.Journal of clinical laboratory analysis · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe long non-coding RNAs (lncRNAs) have been shown as a novel class of transcripts with no protein coding functions. LncRNAs can play diverse roles in cancer cell proliferation, differentiation, metastasis, and apoptosis. However, the exact contributions of lncRNA KDM5B anti-sense RNA 1 (KDM5BAS1) to non-small cell lung cancer (NSCLC) remain poorly understood.
methodsIn current study, we have unraveled a novel function of KDM5BAS1 in NSCLC.
resultsWe found that KDM5BAS1 was significantly overexpressed in tumor specimens and selected cancerous cell lines. Meanwhile, higher KDM5BAS1 expression predicted poor overall survival. Increased KDM5BAS1 expression can promote proliferation or migration and inhibit apoptosis in H1838 and H1299 cells. Furthermore, knocking down of KDM5BAS1 levels can also reduce tumor growth in in vivo implantation experiments. Overexpression of KDM5BAS1 also decreased the caspase-3 immunostaining but enhanced Ki-67 staining.
conclusionTaken together, our findings indicated that KDM5BAS1 might play an oncogenic role in NSCLC and provided clues into pharmacological intervention targeting KDM5BAS1.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.